Immunomedics Inc.Find Ratings Reports
IMMUNOMEDICS INC's gross profit margin for the second quarter of its fiscal year 2018 has significantly increased when compared to the same period a year ago. The company has grown sales and net income significantly, outpacing the average growth rates of competitors within its industry. IMMUNOMEDICS INC has average liquidity. Currently, the Quick Ratio is 1.19 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 123.16% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY18||Q2 FY17|
|Net Sales ($mil)||0.6||0.38|
|Net Income ($mil)||-2.51||-24.45|
|Balance Sheet||Q2 FY18||Q2 FY17|
|Cash & Equiv. ($mil)||139.75||46.61|
|Total Assets ($mil)||155.95||53.12|
|Total Debt ($mil)||19.69||97.72|
|Profitability||Q2 FY18||Q2 FY17|
|Gross Profit Margin||-4859.63||-3939.32|
|Return on Assets||-149.93||-132.78|
|Return on Equity||-1355.73||0.0|
|Debt||Q2 FY18||Q2 FY17|
|Share Data||Q2 FY18||Q2 FY17|
|Shares outstanding (mil)||161.27||105.99|
|Div / share||0.0||0.0|
|Book value / share||0.11||-0.7|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||3086120.0||3210061.0|
HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 150.51 indicates a significant premium versus the S&P 500 average of 3.26 and a significant premium versus the industry average of 15.63. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, IMMUNOMEDICS INC seems to be trading at a premium to investment alternatives within the industry.
|IMMU NM||Peers 46.82||IMMU NM||Peers 41.91|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
IMMU's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
IMMU's P/CF is negative making the measure meaningless.
|IMMU NM||Peers 28.60||IMMU NA||Peers 0.35|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
IMMU's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|IMMU 150.51||Peers 15.63||IMMU -180.55||Peers 2.21|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
IMMU is trading at a significant premium to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, IMMU is expected to significantly trail its peers on the basis of its earnings growth rate.
|IMMU 798.40||Peers 87.22||IMMU 9.97||Peers 120.94|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
IMMU is trading at a significant premium to its industry.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
IMMU significantly trails its peers on the basis of sales growth